Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS

Eur J Pharmacol. 2024 Jan 15:963:176266. doi: 10.1016/j.ejphar.2023.176266. Epub 2023 Dec 12.

Abstract

Hydrogen sulfide (H2S) is a gasotransmitter implied in metabolic diseases, insulin resistance, obesity, and type 2 Diabetes Mellitus. This study aimed to determine the effect of chronic administration of sodium hydrosulfide (NaHS; inorganic H2S donor), L-Cysteine (L-Cys; substrate of H2S producing enzymes) and DL-Propargylglycine (DL-PAG; cystathionine-gamma-lyase inhibitor) on the vascular dysfunction induced by insulin resistance in rat thoracic aorta. For this purpose, 72 animals were divided into two main sets that received: 1) tap water (control group; n = 12); and 2) fructose 15% w/v in drinking water [insulin resistance group (IR); n = 60] for 20 weeks. After 16 weeks, the group 2 was divided into five subgroups (n = 12 each), which received daily i. p. injections during 4 weeks of: 1) non-treatment (control); 2) vehicle (phosphate buffer saline; PBS, 1 ml/kg); 3) NaHS (5.6 mg/kg); 4) L-Cys (300 mg/kg); and (5) DL-PAG (10 mg/kg). Hemodynamic variables, metabolic variables, vascular function, ROS levels and the expression of p-eNOS and eNOS were determined. IR induced: 1) hyperinsulinemia; 2) increased HOMA-index; 3) decreased Matsuda index; 4) hypertension, vascular dysfunction, increased ROS levels; 5) increased iNOS, and 6) decreased CSE, p-eNOS and eNOS expression. Furthermore, IR did not affect contractile responses to norepinephrine. Interestingly, NaHS and L-Cys treatment, reversed IR-induced impairments and DL-PAG treatment decreased and increased the HOMA and Matsuda index, respectively. Taken together, these results suggest that NaHS and L-Cys decrease the metabolic and vascular alterations induced by insulin resistance by reducing oxidative stress and activating eNOS. Thus, hydrogen sulfide may have a therapeutic application.

Keywords: Hydrogen sulfide; Insulin resistance; Vascular dysfunction; Vasoconstriction; Vasorelaxation.

MeSH terms

  • Animals
  • Cystathionine gamma-Lyase / antagonists & inhibitors
  • Cystathionine gamma-Lyase / metabolism
  • Cysteine / metabolism
  • Cysteine / pharmacology
  • Cysteine / therapeutic use
  • Diabetes Mellitus, Type 2* / complications
  • Hydrogen Sulfide* / metabolism
  • Hydrogen Sulfide* / pharmacology
  • Hydrogen Sulfide* / therapeutic use
  • Hypertension* / drug therapy
  • Hypertension* / metabolism
  • Insulin Resistance* / physiology
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects
  • Rats
  • Reactive Oxygen Species

Substances

  • Cystathionine gamma-Lyase
  • Cysteine
  • Hydrogen Sulfide
  • Nitric Oxide Synthase Type III
  • Reactive Oxygen Species
  • sodium bisulfide